Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.
Childhood Cancer Survivor Study
cancer survivor
neuroblastoma
neurocognitive
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 09 2023
15 09 2023
Historique:
revised:
12
04
2023
received:
01
07
2022
accepted:
13
04
2023
pmc-release:
15
03
2024
medline:
21
8
2023
pubmed:
18
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
Despite survival improvements, there is a paucity of data on neurocognitive outcomes in neuroblastoma survivors. This study addresses this literature gap. Neurocognitive impairments in survivors were compared to sibling controls from the Childhood Cancer Survivor Study (CCSS) using the CCSS Neurocognitive Questionnaire. Impaired emotional regulation, organization, task efficiency, and memory defined as scores ≥90th percentile of sibling norms. Modified Poisson regression models evaluated associations with treatment exposures, era of diagnosis, and chronic conditions. Analyses were stratified by age at diagnosis (≤1 and >1 year) as proxy for lower versus higher risk disease. Survivors (N = 837; median [range] age, 25 [17-58] years, age diagnosed, 1 [0-21] years) were compared to sibling controls (N = 728; age, 32 [16-43] years). Survivors had higher risk of impaired task efficiency (≤1 year relative risk [RR], 1.48; 95% confidence interval [CI], 1.08-2.03; >1 year RR, 1.58; 95% CI, 1.22-2.06) and emotional regulation (≤1 year RR, 1.51; 95% CI, 1.07-2.12; >1 year RR, 1.44; 95% CI, 1.06-1.95). Impaired task efficiency associated with platinum exposure (≤1 year RR, 1.74; 95% CI, 1.01-2.97), hearing loss (≤1 year RR, 1.95; 95% CI, 1.26-3.00; >1 year RR, 1.56; 95% CI, 1.09-2.24), cardiovascular (≤1 year RR, 1.83; 95% CI, 1.15-2.89; >1 year RR, 1.74; 95% CI, 1.12-2.69), neurologic (≤1 year RR, 2.00; 95% CI, 1.32-3.03; >1 year RR, 2.29; 95% CI, 1.64-3.21), and respiratory (>1 year RR, 2.35; 95% CI, 1.60-3.45) conditions. Survivors ≤1 year; female sex (RR, 1.54; 95% CI, 1.02-2.33), cardiovascular (RR, 1.71; 95% CI, 1.08-2.70) and respiratory (RR, 1.99; 95% CI, 1.14-3.49) conditions associated impaired emotional regulation. Survivors were less likely to be employed full-time (p < .0001), graduate college (p = .035), and live independently (p < .0001). Neuroblastoma survivors report neurocognitive impairment impacting adult milestones. Identified health conditions and treatment exposures can be targeted to improve outcomes. Survival rates continue to improve in patients with neuroblastoma. There is a lack of information regarding neurocognitive outcomes in neuroblastoma survivors; most studies examined survivors of leukemia or brain tumors. In this study, 837 adult survivors of childhood neuroblastoma were compared to siblings from the Childhood Cancer Survivorship Study. Survivors had a 50% higher risk of impairment with attention/processing speed (task efficiency) and emotional reactivity/frustration tolerance (emotional regulation). Survivors were less likely to reach adult milestones such as living independently. Survivors with chronic health conditions are at a higher risk of impairment. Early identification and aggressive management of chronic conditions may help mitigate the level of impairment.
Sections du résumé
BACKGROUND
Despite survival improvements, there is a paucity of data on neurocognitive outcomes in neuroblastoma survivors. This study addresses this literature gap.
METHODS
Neurocognitive impairments in survivors were compared to sibling controls from the Childhood Cancer Survivor Study (CCSS) using the CCSS Neurocognitive Questionnaire. Impaired emotional regulation, organization, task efficiency, and memory defined as scores ≥90th percentile of sibling norms. Modified Poisson regression models evaluated associations with treatment exposures, era of diagnosis, and chronic conditions. Analyses were stratified by age at diagnosis (≤1 and >1 year) as proxy for lower versus higher risk disease.
RESULTS
Survivors (N = 837; median [range] age, 25 [17-58] years, age diagnosed, 1 [0-21] years) were compared to sibling controls (N = 728; age, 32 [16-43] years). Survivors had higher risk of impaired task efficiency (≤1 year relative risk [RR], 1.48; 95% confidence interval [CI], 1.08-2.03; >1 year RR, 1.58; 95% CI, 1.22-2.06) and emotional regulation (≤1 year RR, 1.51; 95% CI, 1.07-2.12; >1 year RR, 1.44; 95% CI, 1.06-1.95). Impaired task efficiency associated with platinum exposure (≤1 year RR, 1.74; 95% CI, 1.01-2.97), hearing loss (≤1 year RR, 1.95; 95% CI, 1.26-3.00; >1 year RR, 1.56; 95% CI, 1.09-2.24), cardiovascular (≤1 year RR, 1.83; 95% CI, 1.15-2.89; >1 year RR, 1.74; 95% CI, 1.12-2.69), neurologic (≤1 year RR, 2.00; 95% CI, 1.32-3.03; >1 year RR, 2.29; 95% CI, 1.64-3.21), and respiratory (>1 year RR, 2.35; 95% CI, 1.60-3.45) conditions. Survivors ≤1 year; female sex (RR, 1.54; 95% CI, 1.02-2.33), cardiovascular (RR, 1.71; 95% CI, 1.08-2.70) and respiratory (RR, 1.99; 95% CI, 1.14-3.49) conditions associated impaired emotional regulation. Survivors were less likely to be employed full-time (p < .0001), graduate college (p = .035), and live independently (p < .0001).
CONCLUSIONS
Neuroblastoma survivors report neurocognitive impairment impacting adult milestones. Identified health conditions and treatment exposures can be targeted to improve outcomes.
PLAIN LANGUAGE SUMMARY
Survival rates continue to improve in patients with neuroblastoma. There is a lack of information regarding neurocognitive outcomes in neuroblastoma survivors; most studies examined survivors of leukemia or brain tumors. In this study, 837 adult survivors of childhood neuroblastoma were compared to siblings from the Childhood Cancer Survivorship Study. Survivors had a 50% higher risk of impairment with attention/processing speed (task efficiency) and emotional reactivity/frustration tolerance (emotional regulation). Survivors were less likely to reach adult milestones such as living independently. Survivors with chronic health conditions are at a higher risk of impairment. Early identification and aggressive management of chronic conditions may help mitigate the level of impairment.
Identifiants
pubmed: 37199722
doi: 10.1002/cncr.34847
pmc: PMC10523930
mid: NIHMS1897510
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2904-2914Subventions
Organisme : NCI NIH HHS
ID : U24 CA055727
Pays : United States
Informations de copyright
© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
J Pediatr Psychol. 2005 Jan-Feb;30(1):79-84
pubmed: 15610987
J Pers Med. 2015 Apr 10;5(2):83-90
pubmed: 25867598
Neuropsychol Rev. 2018 Jun;28(2):123-175
pubmed: 29270773
Dev Disabil Res Rev. 2008;14(3):251-8
pubmed: 18924157
Neuropsychology. 2014 Sep;28(5):791-800
pubmed: 24773415
Cancer Res. 1971 Dec;31(12):2098-103
pubmed: 5120301
Arch Otolaryngol Head Neck Surg. 2004 May;130(5):556-62
pubmed: 15148176
N Engl J Med. 1999 Oct 14;341(16):1165-73
pubmed: 10519894
J Clin Oncol. 2005 Dec 1;23(34):8588-96
pubmed: 16314621
World J Diabetes. 2016 Sep 15;7(17):412-22
pubmed: 27660698
Brain. 2009 Jan;132(Pt 1):45-56
pubmed: 19168454
Neuropsychology. 2015 Jan;29(1):31-44
pubmed: 24933482
Otolaryngol Clin North Am. 2015 Dec;48(6):983-94
pubmed: 26433444
Support Care Cancer. 2014 Aug;22(8):2251-60
pubmed: 24671433
N Engl J Med. 2010 Sep 30;363(14):1313-23
pubmed: 20879880
Pediatr Clin North Am. 2020 Apr;67(2):259-273
pubmed: 32122559
J Clin Oncol. 2015 Nov 10;33(32):3774-80
pubmed: 26304888
Nature. 2017 May 11;545(7653):219-223
pubmed: 28467827
J Clin Oncol. 2013 Dec 10;31(35):4407-15
pubmed: 24190124
J Pediatr Hematol Oncol. 2014 Jan;36(1):8-15
pubmed: 24345882
Am Psychol. 2017 May-Jun;72(4):326-338
pubmed: 28481580
CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
pubmed: 24890451
J Pediatr Psychol. 2005 Jan-Feb;30(1):51-63
pubmed: 15610985
J Clin Oncol. 2014 Feb 20;32(6):527-34
pubmed: 24419114
Cancer. 1972 Dec;30(6):1595-9
pubmed: 4641765
Pediatr Blood Cancer. 2009 Aug;53(2):156-61
pubmed: 19405135
J Clin Oncol. 2015 Jul 1;33(19):2205-11
pubmed: 25987702
J Clin Oncol. 2013 Sep 20;31(27):3378-88
pubmed: 23960182
J Clin Oncol. 2018 Jul 20;36(21):2181-2189
pubmed: 29874137
Ann Neurol. 2004 Sep;56(3):351-60
pubmed: 15349862
Pediatr Blood Cancer. 2005 Sep;45(3):324-32
pubmed: 15714447
Cancer. 2008 Oct 15;113(8):2188-97
pubmed: 18792068
J Am Coll Cardiol. 2017 May 9;69(18):2279-2289
pubmed: 28473132
Cancer. 2017 Feb 1;123(3):521-528
pubmed: 27764524
J Clin Oncol. 2009 May 10;27(14):2308-18
pubmed: 19364948
Pediatr Blood Cancer. 2011 Sep;57(3):454-60
pubmed: 21618410
Arch Pediatr Adolesc Med. 2007 Aug;161(8):798-806
pubmed: 17679663
J Clin Oncol. 2009 May 10;27(14):2339-55
pubmed: 19364955
JAMA. 2019 Aug 27;322(8):746-755
pubmed: 31454045
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
Crit Rev Oncol Hematol. 2016 Jul;103:37-48
pubmed: 27233118
J Clin Oncol. 2009 May 10;27(14):2319-27
pubmed: 19364957
Neuropsychology. 2009 Nov;23(6):705-17
pubmed: 19899829
Pediatr Blood Cancer. 2013 Jun;60(6):985-93
pubmed: 23255319
J Neurosurg. 2000 Oct;93(4):539-45
pubmed: 11014529
J Clin Oncol. 2012 Oct 10;30(29):3618-24
pubmed: 22949149
Pediatrics. 2007 Nov;120(5):e1229-36
pubmed: 17974716
JAMA. 2019 Feb 12;321(6):553-561
pubmed: 30688979